Rogério Vivaldi Coelho
Chief Executive Officer bij SIGILON THERAPEUTICS, INC.
Vermogen: 514 910 $ op 31-07-2023
Profiel
Rogério Vivaldi Coelho was the founder of Minerva Neurosciences, Inc. (founded in 2007) where he held the title of President, Chief Executive Officer & Director in 2014.
He is currently the Chief Executive Officer at Sigilon Therapeutics, Inc. (since 2018) and an Independent Director at Crinetics Pharmaceuticals, Inc. (since 2022).
In his former positions, he served as a Director at Mind-NRG SARL in 2014, President-Rare Disease, Renal & Endocrine, SVP at Genzyme Corp.
from 1997 to 2014, Chief Commercial Officer at Spark Therapeutics, Inc. from 2015 to 2016, and Chief Global Therapeutics Officer & Executive VP at Bioverativ, Inc. from 2016 to 2018.
Dr. Vivaldi Coelho holds a doctorate degree from the Federal University of Rio de Janeiro and an MBA from COPPEAD Graduate School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-06-2023 | 11 000 ( 0.01% ) | 514 910 $ | 31-03-2024 | |
| 11-08-2023 | 0 ( -.--% ) | - $ | 31-07-2023 |
Actieve functies van Rogério Vivaldi Coelho
| Bedrijven | Functie | Begin |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Chief Executive Officer | 14-08-2018 |
| CRINETICS PHARMACEUTICALS, INC. | Director/Board Member | 03-01-2022 |
Eerdere bekende functies van Rogério Vivaldi Coelho
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOVERATIV INC | Corporate Officer/Principal | 01-01-2018 |
| SPARK THERAPEUTICS, INC. | Director/Board Member | 05-01-2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| MINERVA NEUROSCIENCES, INC. | Founder | 20-11-2014 |
Mind-NRG SARL
 Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Director/Board Member | 20-11-2014 |
Opleiding van Rogério Vivaldi Coelho
| Federal University of Rio de Janeiro | Doctorate Degree |
| COPPEAD Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MINERVA NEUROSCIENCES, INC. | Health Technology |
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Mind-NRG SARL
Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Health Services |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
